Repros Therapeutics Inc (RPRX)

[docbanker]

I understand your frustration.
We have a few things going on here to account for the stock price in my opinion (and not some looming horrendous news like a failure or a financing):
i) Continued poor small-cap and small-cap btk tape (look at IDEV and its clinical progress and the stock goes DOWN- and yes if ANdroxal crushes Nebido, there is still other stuff there like Sanctura)
ii) Overwhelming negative sentiment on Androxal- how did sentiment get to the point where everyone is giving it ZERO value and near zero chance of clear clinical pathway?
iii) CMO van As taking a bit longer than everyone wants to complete regulatory deadlines- the good is that he is being thorough, the bad is that timelines seem to slip a month here or a month there
iv) Lack of a breadth of coverage- research is not the end all be all, and I have been reminded by some who read "Good to Great" that many of those companies with the highest returns were sleepier (lack of brokerage lift)- this can be overcome in my opinion with execution and insider support- we DO NEED more insider buying in my opinion. Aside from JP, ownership is weak. I think the board members with regulatory experience are probably not "independently wealthy" and can be excused from owning a lesser # of shares but some of the folks- I think one has private equity experience- own far too low a number of shares- that one PE idiot bought 100 shares or something last year- made her look dumber and poorer than she probably is.